Protocol Number: 03-C-0216

Title:

A Groupwide Biology and Banking Study for Ewing Sarcoma: Children's Oncology Group

Number:

03-C-0216

Summary:

Background:

It is clear that improved understanding of the basic biology of Ewing sarcoma will ultimately lead to improved treatment approaches to this disease. With the identification of the invariant EWS-ETS fusion gene in these tumors, the search for new downstream target genes is ongoing with hopes of identifying new molecular treatment targets for drug development. Many important questions remain to be resolved, including the effect of translocation type on prognosis, the effect of submicroscopic molecular-only disease on long-term outcome and the identification of molecular targets and molecular determinants of prognosis.

Objectives:

-To develop a mechanism to collect and distribute tumor specimens to various investigators and a system to prioritize and develop quality control measures for central data reporting of studies undertaken.

-To determine the prognostic significance of translocation subtype in Ewing sarcoma.

-To determine the prognostic significance of MRD detection in bone marrow specimens by RT-PCR

-To determine if serum levels of IGF are of significance in the outcome of patients with Ewing sarcoma.

-To determine if RNA expression profiles performed on diagnostic specimens will allow for the identification of newer prognostic categories and potentially new molecular targets for treatment in Ewing sarcoma.

-To identify new targets for therapy.

-To identify a bank of Ewing sarcoma xenografts in SCID mice.

-To establish clinical proteomics as a resource for investigations of altered signaling molecules in the pathogenesis of Ewing sarcoma.

Eligibility:

-Newly diagnosed or recurrent Ewing sarcoma patients, prior to treatment.

-Specimen requirements consisting of paraffin embedded block or 20 unstained slides and pretreatment blood and tissue specimens.

-For patients who enroll on a Ewing sarcoma therapeutic trial : Agreement to obtain specimens at additional designated time-points during therapy, at the time of surgery, at the completion of therapy and at relapse.

Design:

This study is designed to analyze biological factors of Ewing tumors, and for those patients enrolled on the local and metastatic Ewing sarcoma protocols, to relate the tumor characteristics and treatment outcomes. With this information it will be possible to further refine the aims of the next biology study. This study will also establish a bank for Ewing sarcoma tumors.

Sponsoring Institute:

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria: This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Special Instructions:

Currently Not Provided

Keyword(s):

Tissue Banking

Tumor Studies

Recruitment Keyword(s):

Ewing Sarcoma

Condition(s):

Ewing's Sarcoma

Investigational Drug(s):

None

Investigational Device(s):

None

Interventions:

None

Supporting Site:

National Cancer Institute

Contact(s):

This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Citation(s):

Patricio MB, Vilhena M, Neves M, Raposo S, Catita J, De Sousa V, Martins AG. Ewing's sarcoma in children: twenty-five years of experience at the Instituto Portuges de Oncologia de Francisco Gentil (I.P.O.F.G.). J Surg Oncol. 1991 May;47(1):37-40.

Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, Horowitz ME. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389-95.

Gasparini M, Lombardi F, Ballerini E, Gandola L, Gianni MC, Massimino M, Rottoli L, Fossati-Bellani F. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med Pediatr Oncol. 1994;23(5):406-12.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department Clinical Research Informatics, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 08/13/2009